Cytomegalovirus immediate-early antigen 2 mRNA (IE2 mRNA)

Human cytomegalovirus (HCMV) immediate-early antigen 2 (IE2) mRNA is a critical viral transcript encoded by the UL122 gene. The IE2 protein translated from this mRNA serves as a master transcriptional regulator, essential for the transition of the virus from the immediate-early to the early and late stages of its lytic cycle (UniProt: P16753). IE2 works by transactivating various viral and host promoters while autoregulating its own expression to ensure efficient viral replication and the suppression of host immune responses (PubMed: 12151631). In clinical medicine, IE2 mRNA is a landmark therapeutic target, notably for the drug fomivirsen, which was the first antisense oligonucleotide (ASO) to receive FDA approval (PubChem: CID 16131435). Fomivirsen targets a specific sequence within the IE2 mRNA, forming a duplex that inhibits the translation of the IE2 protein and effectively halts the production of infectious viral particles (PubMed: 9811464). While primarily used to treat CMV retinitis in immunocompromised patients, targeting this mRNA requires careful monitoring for ocular side effects such as inflammation and increased intraocular pressure (NIH: StatPearls).

Other names

Human cytomegalovirus UL122 mRNAHCMV IE2 mRNAImmediate-early protein 2 mRNACytomegalovirus UL122 transcript

Antisense oligonucleotide-mediated inhibition of translation via RNase H-mediated cleavage or steric hindrance of the ribosomal complex.